Altamira Therapeutics Ltd.
CYTOF
$0.07
$0.009916.47%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -61.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -61.07% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.75% | -11.75% | -- | -- | -48.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 55.81% | 55.81% | -- | -- | 70.84% |
| Total Operating Expenses | 7.16% | 7.16% | -- | -- | -59.52% |
| Operating Income | -7.16% | -7.16% | -- | -- | 58.12% |
| Income Before Tax | 4.07% | 4.07% | -- | -- | 47.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.07% | 4.07% | -- | -- | 47.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.00% | 27.00% | -- | -- | 30.44% |
| EBIT | -7.16% | -7.16% | -- | -- | 58.12% |
| EBITDA | -- | -- | -- | -- | 58.13% |
| EPS Basic | 92.56% | 92.56% | 92.06% | 93.14% | 87.16% |
| Normalized Basic EPS | 90.30% | 90.30% | -- | -- | 90.22% |
| EPS Diluted | 92.56% | 92.56% | 92.06% | 93.14% | 87.16% |
| Normalized Diluted EPS | 90.30% | 90.30% | -- | -- | 90.22% |
| Average Basic Shares Outstanding | 881.29% | 881.29% | 979.78% | -- | 442.64% |
| Average Diluted Shares Outstanding | 881.29% | 881.29% | 979.78% | 384.99% | 442.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
